The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study
Abstract
OBJECTIVE: This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia. METHOD: Consenting patients were enrolled in the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project. In phase 1, patients were randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months. Clozapine was included for patients who chose this pathway after discontinuing phase 1 due to inefficacy; all other patients received another second-generation antipsychotic. Psychosocial functioning was assessed using the Quality of Life Scale. RESULTS: Psychosocial functioning modestly improved for the one-third of phase 1 patients who reached the primary Quality of Life Scale analysis endpoint of 12 months (average effect size 0.19 SD units). Although for several of the drugs individually there were significant changes from baseline, overall there were no significant differences between the different agents. Results were similar at 6 and 18 months. There were no significant differences among the treatment groups in the amount of change in the Quality of Life Scale total score or subscale scores at 6, 12, or 18 months. Patients treated with clozapine in the efficacy pathway made comparable gains. Early treatment discontinuations, especially among patients most impaired at baseline, limited the ability to achieve more substantial functional gains. CONCLUSIONS: All antipsychotic treatment groups in all phases made modest improvements in psychosocial functioning. There were no differences among them after 6, 12, or 18 months. More substantial improvements would likely require more intensive adjunctive psychosocial rehabilitation interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationThe Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Self-citationHogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,028
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Self-citationThe Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Reliability and validity of a depression rating scale for schizophrenics
Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992) · Schizophrenia Research · doi:10.1016/0920-9964(92)90003-n · Cited by 651
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Self-citationGender differences in schizophrenia
Häfner, H. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00125-7 · Cited by 565
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Self-citationDiagnosis of Alcohol Use Disorders in Schizophrenia
Drake, R. E., Osher, F. C., Noordsy, D. L., Hurlbut, S. C., Teague, G. B., & Beaudett, M. S. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.1.57 · Cited by 497
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
Self-citationMeltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990) · Psychiatric Services · doi:10.1176/ps.41.8.892 · Cited by 338
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Self-citationRosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Self-citationMarley, E. (1962) · Psychopharmacologia · doi:10.1007/bf00411372 · Cited by 218
Lambert, M., & Naber, D. (2004) · CNS Drugs · doi:10.2165/00023210-200418002-00002 · Cited by 171
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Swartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., Canive, J. M., Miller, D. D., Reimherr, F., McGee, M., Khan, A., et al. (2006) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000202575.79453.6e · Cited by 146
Prognostic Variables at Intake and Long-Term Level of Function in Schizophrenia
Siegel, S. J., Irani, F., Brensinger, C. M., Kohler, C. G., Bilker, W. B., Ragland, J. D., Kanes, S., Gur, R. C., & Gur, R. E. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.433 · Cited by 138
Subjective well-being and quality of life under atypical antipsychotic treatment
Karow, A., & Naber, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1052-z · Cited by 133
Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia
Awad, A. G., & Voruganti, L. N. P. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00004 · Cited by 125
Keefe, R. S. E., Mohs, R. C., Bilder, R. M., Harvey, P. D., Green, M. F., Meltzer, H. Y., Gold, J. M., & Sano, M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006990 · Cited by 121
Self-citationQuality of life in schizophrenia: A review of the literature from 1995 to 2000
Pinikahana, J., Happell, B., Hope, J., & Keks, N. A. (2002) · International Journal of Mental Health Nursing · doi:10.1046/j.1440-0979.2002.00233.x · Cited by 117
Hamilton, S. H. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00111-5 · Cited by 117
Swartz, M. S., Perkins, D. O., Stroup, T. S., McEvoy, J. P., Nieri, J., & Haak, D. C. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006989 · Cited by 109
Self-citationStroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102
Self-citationMeasuring outcome priorities and preferences in people with schizophrenia
Rosenheck, R. A., Stroup, T. S., Keefe, R. S. E., McEvoy, J. M., Swartz, M. S., Perkins, D. O., Hsiao, J., Shumway, M., & Lieberman, J. A. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.6.529 · Cited by 81
Self-citationSwartz, M. S., Wagner, H. R., Swanson, J. W., Stroup, T. S., McEvoy, J. P., McGee, M., Miller, D. D., Reimherr, F. W., Khan, A., Cañive, J. M., et al. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.8.1110 · Cited by 67
Self-citationTracy, K., Adler, L. A., Rotrosen, J., Edson, R., & Lavori, P. W. (1997) · PubMed · Cited by 58
Davis, S. M., Koch, G. G., DAVIS, C. E., & LaVange, L. M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006993 · Cited by 44
Self-citationTargeting Schizophrenia Research to Patient Outcomes
Carpenter, W. T. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.353 · Cited by 17
Research works printed but not linked: 5
- Meltzer HY, 1990, Hosp Community Psychiatry, 41, 892
- Essock SM, 1996, Psychopharmacology Bull, 32, 683
- Keefe RSE, 2006, Neuropsychopharmacology, 4, 1
- Tracy K, 1997, Psychopharmacology Bull, 33, 53
- 10.1176/appi.ajp.163.3.356 · doi:10.1176/appi.ajp.163.3.356
Cited by
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Self-citationSchizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Eack, S. M., Hogarty, G. E., Cho, R. Y., Prasad, K. M. R., Greenwald, D. P., Hogarty, S. S., & Keshavan, M. S. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.63 · Cited by 360
“Todate, theneurobiologicallybased impairments incognition observed in schizophrenia have had limited response to pharmacotherapy(19,20) at the cost of continued disability.(21) In contrast, psychosocial cognitive rehabilitation programs have emerged as effective methods for remediating the cognitive impairments in sch…”
Background
Metadata
- Authors
- Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., Hsiao, J. K., Lieberman, J. A., & for the CATIE Investigators
- Venue
- American Journal of Psychiatry
- Published
- 2007-03
- Volume
- 164
- Issue
- 3
- Pages
- 428-436
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2099704493
- Cited by
- 291
- References
- 35
- FWCI
- 18.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.